Treatment of Multiorgan Sarcoidosis With Tofacitinib.

ABSTRACT:

Objective

Sarcoidosis is an idiopathic inflammatory disorder that is difficult to treat. There is accumulating evidence that constitutive activation of Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling occurs in sarcoidosis and represents a target for treatment. Here we report the efficacy of tofacitinib, a Janus kinase (JAK) inhibitor, in a single patient with multiorgan sarcoidosis.

Methods

A patient with long-standing multiorgan sarcoidosis who was unresponsive to other commonly used therapies, including methotrexate, prednisone, and tumor necrosis factor α blockade, was treated with tofacitinib.

Results

Tofacitinib treatment resulted in clinical remission of cutaneous sarcoidosis lesions and resolution of positron emission tomograp

SUBMITTER: Damsky W 

PROVIDER: S-EPMC7011417 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature